In U251 glioblastoma and BxPc-3 pancreatic carcinoma cells, 50 μM celecoxib reduced MTT growth/survival signal and survivin protein. Several other COX inhibitors had little effect at 100 μM, and the distinct analog DMC also reduced these endpoints. The comparison supports additional cellular actions but does not establish survivin as a direct celecoxib target; the Figure 3 exposure duration was unspecified. [2]
COX inhibition measured by LC-MS/MS
Biochemical assay · Purified ovine COX-1 and ovine COX-2; human recombinant COX-2 [1]
Celecoxib inhibited human COX-2 more potently than the ovine enzymes. The selected numerical endpoints are human COX-2 and ovine COX-1; the disputed ovine COX-2 IC50 is omitted. No human COX-1 was tested.
Literature-Reported Treatment Conditions
- Treatment concentration
- 12 inhibitor concentrations; exact series not tabulated. Arachidonic acid: 5 μM.
- Exposure duration
- 10 min inhibitor preincubation at 37°C; 2 min substrate reaction.
- Method
- PGE2 formation relative to inhibitor-free DMSO control, quantified by LC-MS/MS.
- Vehicle
- DMSO; 2 μL added to 200 μL reaction.
- Reported limits
- Compound purity and lot identity not reported in the retrieved Materials section. Ovine COX-2 numerical discrepancy remains unresolved.
Methods and source locations
Compound reported in the paper: Celecoxib
Reported material and model only; no validation of Adooq lots or equivalence of formulations.
Sections 2.1–2.3 and 3.1–3.2; Table 1; Figure 5
Inhibition of human recombinant COX-2-dependent PGE2 formation: Twelve concentrations each assayed three times; curve fitting of LC-MS/MS PGE2 inhibition. — Table 1 celecoxib row; Figure 5 upper panel; section 2.2
Inhibition of ovine COX-1-dependent PGE2 formation: Same assay design and inhibitor-free DMSO comparison as human COX-2. — Table 1 celecoxib row; Figure 5 lower-right panel; section 2.2
Tumor-cell growth and survivin response
Cell-based study · U251 glioblastoma and BxPc-3 pancreatic carcinoma cells [2]
Celecoxib reduced the MTT growth/survival signal and survivin protein in both models. Other tested NSAIDs/coxibs had little effect at 100 μM; DMC also produced effects. These comparisons support a cellular action beyond a simple shared COX-inhibitor response, but do not establish survivin as a direct binding target or prove that its loss causes cell death.
Literature-Reported Treatment Conditions
- Treatment concentration
- Celecoxib 50 μM; DMC 40 μM; valdecoxib, flurbiprofen, indomethacin, sulindac and rofecoxib 100 μM.
- Exposure duration
- Figure 3 assay duration is not specified in its caption or corresponding MTT/immunoblot methods.
- Method
- Parallel MTT assay and survivin immunoblot with actin loading control; untreated and DMSO controls.
- Vehicle
- DMSO; final solvent concentration below 0.5%.
- Reported limits
- Do not transfer the 48 h exposure from Figure 1 to Figure 3. Figure 3 does not specify replicate number or error-bar semantics; no numerical effect size is extracted.
Methods and source locations
Compound reported in the paper: Celecoxib
Reported material and model only; no validation of Adooq lots or equivalence of formulations.
Results: Down-regulation of survivin is independent of cyclooxygenase-2; Figure 3; Materials and methods
MTT growth/survival signal and survivin protein abundance: MTT and Western blot; actin and untreated/DMSO controls shown. Immunoblots were repeated at least once according to shared methods; no exact percentage inferred from bars. — Figure 3 top/bottom panels and corresponding Results; Materials: Immunoblots and antibodies; MTT assay